OA pain management moves beyond single-drug strategies

Version 1

A new Clinician’s Brief partner podcast puts osteoarthritis pain management back in focus, with pain specialist Dr. Robin Downing urging veterinarians to think beyond a single-drug approach for dogs with OA. The episode, sponsored by PRN Pharmacal, centers on practical strategies for identifying pain, improving quality of life, and building more complete treatment plans as the analgesic toolbox expands. That message lands at a moment when OA care is getting closer scrutiny: AAHA’s 2022 pain management guidelines describe chronic pain care as an evolving area and support multimodal treatment, while newer options such as anti-NGF monoclonal antibodies have broadened first-line choices for canine OA. (cliniciansbrief.com)

Why it matters: For veterinary professionals, the takeaway is less about one product and more about process. OA pain management now requires stronger screening, clearer communication with pet parents, and more deliberate reassessment as practices balance NSAIDs, rehab, weight management, environmental modification, adjunctive therapies, and newer biologics. That’s especially relevant after FDA safety-related labeling changes for Librela in February 2025 added post-approval adverse-event language, required a client information sheet before each injection, and emphasized discussing an exercise plan as mobility improves. (aaha.org)

What to watch: Expect more attention on how clinics standardize multimodal OA protocols, monitor outcomes over time, and counsel pet parents as new efficacy and safety data continue to emerge. (fda.gov)